Table 5.

Univariate analyses of progression-free survival by prognostic factors (P < 0.1)

No. patientsEstimated median PFS (mo)Estimated % PFS at 1 yRelative hazard rate (95% CI)P (log-rank)
All patients666.837
Age group
    ≤65319.7501.00 (reference)0.016
    >65354.8262.07 (1.13-3.81)
β2M (ND* = 1), mg/L
    ≤3269.2371.00 (reference)0.017
    >3 to <6236.5501.28 (0.62-2.62)
    ≥6163.8262.45 (1.19-5.03)
Celecoxib dose (g)
    ≥402612.7511.00 (reference)0.039
    <40404.6281.91 (1.02-3.56)
Haemoglobin (g/L)
    ≥1103012.7541.00 (reference)0.052
    <110364.1241.81 (0.99-3.32)
Plasma cells (ND* = 2), %
    ≤50518.1411.00 (reference)0.073
    >50136.7291.83 (0.94-3.58)
  • Abbreviation: PFS, progression-free survival.

  • * ND, not done (number of patients not assessed).

  • Trend.

  • Total celecoxib dose in first 8 wks.